Common use of REPRESENTATIONS AND WARRANTIES REGARDING THE COMPANY GROUP Clause in Contracts

REPRESENTATIONS AND WARRANTIES REGARDING THE COMPANY GROUP. 17 Section 4.1.Organization of the Company and the Company Group 17 Section 4.2.Authorization 18 Section 4.3.Noncontravention 18 Section 4.4.Capitalization 18 Section 4.5.Subsidiaries of the Company 20 Section 4.6.Consents, Government Authorizations 20 Section 0.0.Xxxxxxxxx Statements 20 Section 4.8.Absence of Certain Changes 20 Section 0.0.Xxx Matters 21 Section 4.10.Real Property 22 Section 4.11.Intellectual Property 22 Section 4.12.Environmental Matters 23 Section 4.13.Contracts 23 Section 0.00.Xxxxxxxxx 25 Section 4.15.Litigation 26 Section 4.16.Employee Matters 26 Section 0.00.Xxxxx Compliance 28 Section 4.18.Brokers’ Fees 28 Section 4.19.Permits 28 Section 4.20.Transaction with Affiliates; Ownership of Assets 28 Section 0.00.Xx Additional Representations and Warranties 29 ARTICLE V. REPRESENTATIONS AND WARRANTIES REGARDING BUYER AND MERGER SUB 29 Section 5.1.Organization 29 Section 5.2.Authorization 29 Section 5.3.Noncontravention 29 Section 5.4.Consents, Government Authorizations 30 Section 0.0.Xxxxxxxxx Capacity 30 Section 5.6.Litigation 30 Section 5.7.Brokers’ Fees 30 Section 5.8.Information 30 ARTICLE VI. COVENANTS 31 Section 6.1.Conduct of the Company 31 Section 6.2.Access to Information; Confidentiality 33 Section 6.3.Efforts 34 Section 6.4.Approvals 34 Section 6.5.Public Announcements 35 Section 6.6.Notification of Certain Matters 35 Section 6.7.Director and Officer Indemnification 35 Section 6.8.Employee Benefit Arrangements 36 Section 6.9.Post-Closing Access; Preservation of Records 37 Section 6.10.Further Assurances 37 Section 0.00.Xx Solicitation 37 Section 6.12.Supplemental Disclosure 38 Section 0.00.Xxx Treatment of Transactions. 38 Section 6.14.Purchase Price Allocation. 38 ARTICLE VII. CONDITIONS TO CLOSING 39 Section 7.1. Condition Precedent to Obligations of Buyer, Merger Sub and the Company 39 Section 7.2.Conditions Precedent to Obligation of the Company 40 Section 7.3.Conditions Precedent to Obligations of Buyer and Merger Sub 40 ARTICLE VIII. INDEMNIFICATION 41 Section 8.1.Survival 41 Section 8.2.Indemnification 42 Section 8.3.Indemnification Procedures 43 Section 8.4.Limitation on Liability 45 Section 8.5.Calculation of Damages 45 Section 8.6.Exclusive Remedy 46 Section 8.7.Access 46 Section 8.8.Mitigation of Damages 46 Section 8.9.Certain Damages 46 Section 8.10.Release of Escrow Amount 46 ARTICLE IX. MEMBER REPRESENTATIVE 47 Section 9.1.Member Representative 47 Section 9.2.Authority and Rights 47 Section 9.3.Limitations on Liability 48 ARTICLE X. TERMINATION 49 Section 10.1.Termination Events 49 Section 10.2.Effect of Termination 49 ARTICLE XI. MISCELLANEOUS 49 Section 11.1.Parties in Interest 49 Section 11.2.Assignment 49 Section 11.3.Notices 50 Section 11.4.Amendments and Waivers 51 Section 11.5.Exhibits and Disclosure Schedule 51 Section 11.6.Headings 52 Section 00.0.Xxxxxxxxxxxx 52 Section 00.0.Xx Other Representations or Warranties 52 Section 11.9.Entire Agreement 52 Section 11.10.Severability 52 Section 11.11.Expenses 53 Section 11.12.Governing Law 53 Section 11.13.Consent to Jurisdiction; Waiver of Jury Trial 53 Section 11.14.Equitable Remedies 53 Section 11.15.Counterparts 54 SCHEDULES Disclosure Schedule EXHIBITS A Escrow Agreement B Non-Compete Agreements C Consulting Agreement AGREEMENT AND PLAN OF MERGER Agreement and Plan of Merger, dated as of July 9, 2007 (including the Schedules and Exhibits hereto, this “Agreement”), is by and among Noven Pharmaceuticals, Inc., a Delaware corporation (“Buyer”), Noven Acquisition, LLC, a Delaware limited liability company and a wholly-owned subsidiary of Buyer (“Merger Sub”), JDS Pharmaceuticals, LLC, a Delaware limited liability company (the “Company”), and Xxxxx Associates, LLC, solely in its capacity as Member Representative. Buyer, Merger Sub, the Company, and solely in its capacity as such and to the extent applicable, the Member Representative, are referred to collectively herein as the “Parties” and each individually as a “Party.”

REPRESENTATIONS AND WARRANTIES REGARDING THE COMPANY GROUP. 17 7 Section 4.1.Organization of the Company 4.1 Existence and the Company Group 17 Qualification 7 Section 4.2.Authorization 18 4.2 No Conflicts 7 Section 4.3.Noncontravention 18 4.3 Capitalization 7 Section 4.4.Capitalization 18 4.4 Subsidiaries 8 Section 4.5.Subsidiaries of the Company 20 4.5 Financial Statements and Related Information 8 Section 4.6.Consents, Government Authorizations 20 4.6 No Undisclosed Liabilities 8 Section 0.0.Xxxxxxxxx Statements 20 Section 4.8.Absence 4.7 Absence of Certain Changes 20 9 Section 0.0.Xxx 4.8 Litigation 10 Section 4.9 Compliance with Laws; Permits 10 Section 4.10 Tax Matters 21 10 Section 4.10.Real 4.11 Real Property 22 11 Section 4.11.Intellectual 4.12 Title to Tangible Assets 12 Section 4.13 Intellectual Property 22 12 Section 4.12.Environmental 4.14 Material Contracts 13 Section 4.15 Employee Matters 23 14 Section 4.13.Contracts 23 4.16 Environmental Matters 17 Section 0.00.Xxxxxxxxx 25 4.17 Insurance 18 Section 4.15.Litigation 26 4.18 Related Party Transactions 18 Section 4.16.Employee Matters 26 4.19 Bank Accounts 18 Section 0.00.Xxxxx Compliance 28 4.20 Suppliers and Customers 18 Section 4.18.Brokers’ Fees 28 4.21 Performance Bonds 18 Section 4.19.Permits 28 4.22 Investment Experience 19 Section 4.20.Transaction with Affiliates4.23 Restricted Securities 19 Section 4.24 Accredited Investor; Ownership Investment Intent 19 Section 4.25 Sufficiency of Assets 28 19 Section 0.00.Xx Additional Representations and Warranties 29 ARTICLE V. REPRESENTATIONS AND WARRANTIES REGARDING BUYER AND MERGER SUB 29 Section 5.1.Organization 29 Section 5.2.Authorization 29 Section 5.3.Noncontravention 29 Section 5.4.Consents, Government Authorizations 30 Section 0.0.Xxxxxxxxx Capacity 30 Section 5.6.Litigation 30 Section 5.7.Brokers’ Fees 30 Section 5.8.Information 30 ARTICLE VI. COVENANTS 31 Section 6.1.Conduct of the Company 31 Section 6.2.Access to Information; Confidentiality 33 Section 6.3.Efforts 34 Section 6.4.Approvals 34 Section 6.5.Public Announcements 35 Section 6.6.Notification of 4.26 Certain Matters 35 Section 6.7.Director and Officer Indemnification 35 Section 6.8.Employee Benefit Arrangements 36 Section 6.9.Post-Closing Access; Preservation of Records 37 Section 6.10.Further Assurances 37 Section 0.00.Xx Solicitation 37 Section 6.12.Supplemental Disclosure 38 Section 0.00.Xxx Treatment of Transactions. 38 Section 6.14.Purchase Price Allocation. 38 ARTICLE VII. CONDITIONS TO CLOSING 39 Section 7.1. Condition Precedent to Obligations of Buyer, Merger Sub and the Company 39 Section 7.2.Conditions Precedent to Obligation of the Company 40 Section 7.3.Conditions Precedent to Obligations of Buyer and Merger Sub 40 ARTICLE VIII. INDEMNIFICATION 41 Section 8.1.Survival 41 Section 8.2.Indemnification 42 Section 8.3.Indemnification Procedures 43 Section 8.4.Limitation on Liability 45 Section 8.5.Calculation of Damages 45 Section 8.6.Exclusive Remedy 46 Section 8.7.Access 46 Section 8.8.Mitigation of Damages 46 Section 8.9.Certain Damages 46 Section 8.10.Release of Escrow Amount 46 ARTICLE IX. MEMBER REPRESENTATIVE 47 Section 9.1.Member Representative 47 Section 9.2.Authority and Rights 47 Section 9.3.Limitations on Liability 48 ARTICLE X. TERMINATION 49 Section 10.1.Termination Events 49 Section 10.2.Effect of Termination 49 ARTICLE XI. MISCELLANEOUS 49 Section 11.1.Parties in Interest 49 Section 11.2.Assignment 49 Section 11.3.Notices 50 Section 11.4.Amendments and Waivers 51 Section 11.5.Exhibits and Disclosure Schedule 51 Section 11.6.Headings 52 Section 00.0.Xxxxxxxxxxxx 52 Section 00.0.Xx Other Representations or Warranties 52 Section 11.9.Entire Agreement 52 Section 11.10.Severability 52 Section 11.11.Expenses 53 Section 11.12.Governing Law 53 Section 11.13.Consent to Jurisdiction; Waiver of Jury Trial 53 Section 11.14.Equitable Remedies 53 Section 11.15.Counterparts 54 SCHEDULES Disclosure Schedule EXHIBITS A Escrow Agreement B Non-Compete Agreements C Consulting Agreement AGREEMENT AND PLAN OF MERGER Agreement and Plan of Merger, dated as of July 9, 2007 (including the Schedules and Exhibits hereto, this “Agreement”), is by and among Noven Pharmaceuticals, Inc., a Delaware corporation (“Buyer”), Noven Acquisition, LLC, a Delaware limited liability company and a wholly-owned subsidiary of Buyer (“Merger Sub”), JDS Pharmaceuticals, LLC, a Delaware limited liability company (the “Company”), and Xxxxx Associates, LLC, solely in its capacity as Member Representative. Buyer, Merger Sub, the Company, and solely in its capacity as such and to the extent applicable, the Member Representative, are referred to collectively herein as the “Parties” and each individually as a “Party.”Disclaimers 19

REPRESENTATIONS AND WARRANTIES REGARDING THE COMPANY GROUP. 17 Section 4.1.Organization of the Company and the Company Group 17 2.1 Organization; Good Standing; Power 19 Section 4.2.Authorization 18 Section 4.3.Noncontravention 18 Section 4.4.Capitalization 18 Section 4.5.Subsidiaries of the Company 2.2 Authority; Enforceability 20 Section 4.6.Consents, Government Authorizations 2.3 Consents; Absence of Conflicts 20 Section 0.0.Xxxxxxxxx Statements 20 2.4 Capitalization 21 Section 4.8.Absence 2.5 Subsidiaries 22 Section 2.6 Financial Statements; No Undisclosed Liabilities 23 Section 2.7 Affiliate Transactions 24 Section 2.8 Real Property 24 Section 2.9 Personal Property 26 Section 2.10 Permits 26 Section 2.11 Contracts 26 Section 2.12 Intellectual Property; Information Technology 30 Section 2.13 Data Privacy and Security 33 Section 2.14 Brokers’ Fees 35 Section 2.15 Absence of Certain Changes 20 Section 0.0.Xxx Matters 21 Section 4.10.Real Property 22 Section 4.11.Intellectual Property 22 Section 4.12.Environmental Matters 23 Section 4.13.Contracts 23 Section 0.00.Xxxxxxxxx 25 Section 4.15.Litigation 26 Section 4.16.Employee Matters 26 Section 0.00.Xxxxx Compliance 28 Section 4.18.Brokers’ Fees 28 Section 4.19.Permits 28 Section 4.20.Transaction with Affiliates; Ownership of Assets 28 Section 0.00.Xx Additional Representations and Warranties 29 ARTICLE V. REPRESENTATIONS AND WARRANTIES REGARDING BUYER AND MERGER SUB 29 Section 5.1.Organization 29 Section 5.2.Authorization 29 Section 5.3.Noncontravention 29 Section 5.4.Consents, Government Authorizations 30 Section 0.0.Xxxxxxxxx Capacity 30 Section 5.6.Litigation 30 Section 5.7.Brokers’ Fees 30 Section 5.8.Information 30 ARTICLE VI. COVENANTS 31 Section 6.1.Conduct of the Company 31 Section 6.2.Access to Information; Confidentiality 33 Section 6.3.Efforts 34 Section 6.4.Approvals 34 Section 6.5.Public Announcements Developments 35 Section 6.6.Notification of Certain Matters 2.16 Legal Compliance 35 Section 6.7.Director and Officer Indemnification 2.17 Taxes 35 Section 6.8.Employee Benefit Arrangements 36 Section 6.9.Post-Closing Access; Preservation of Records 37 Section 6.10.Further Assurances 37 Section 0.00.Xx Solicitation 37 Section 6.12.Supplemental Disclosure 2.18 Litigation 38 Section 0.00.Xxx Treatment of Transactions. 2.19 Employees; Employee Relations 38 Section 6.14.Purchase Price Allocation. 38 ARTICLE VII. CONDITIONS TO CLOSING 39 Section 7.1. Condition Precedent to Obligations of Buyer, Merger Sub and the Company 39 Section 7.2.Conditions Precedent to Obligation of the Company 40 Section 7.3.Conditions Precedent to Obligations of Buyer and Merger Sub 40 ARTICLE VIII. INDEMNIFICATION 2.20 Employee Benefit Matters 41 Section 8.1.Survival 41 2.21 Environmental Matters 44 Section 8.2.Indemnification 42 2.22 Anti-Corruption and Anti-Bribery Laws 44 Section 8.3.Indemnification Procedures 43 2.23 Export Controls 48 Section 8.4.Limitation on Liability 45 Section 8.5.Calculation of Damages 45 Section 8.6.Exclusive Remedy 46 Section 8.7.Access 46 Section 8.8.Mitigation of Damages 46 Section 8.9.Certain Damages 46 Section 8.10.Release of Escrow Amount 46 ARTICLE IX. MEMBER REPRESENTATIVE 47 Section 9.1.Member Representative 47 Section 9.2.Authority and Rights 47 Section 9.3.Limitations on Liability 48 ARTICLE X. TERMINATION 2.24 Insurance 49 Section 10.1.Termination Events 2.25 Debt and Debt-Like Items 49 Section 10.2.Effect of Termination 49 ARTICLE XI. MISCELLANEOUS 2.26 Solvency 49 Section 11.1.Parties in Interest 49 Section 11.2.Assignment 49 Section 11.3.Notices 2.27 Customers and Suppliers 50 Section 11.4.Amendments 2.28 Bank Accounts 50 Section 2.29 Products and Waivers Services 50 Section 2.30 Investment Representations 51 Section 11.5.Exhibits and Disclosure Schedule 2.31 Members 51 Section 11.6.Headings 2.32 COVID-19 51 Section 2.33 Company Plan 52 Section 00.0.Xxxxxxxxxxxx 2.34 Information Supplied 52 Section 00.0.Xx 2.35 No Other Representations or Warranties 52 Section 11.9.Entire Agreement 52 Section 11.10.Severability 52 Section 11.11.Expenses 53 Section 11.12.Governing Law 53 Section 11.13.Consent to Jurisdiction; Waiver of Jury Trial 53 Section 11.14.Equitable Remedies 53 Section 11.15.Counterparts 54 SCHEDULES Disclosure Schedule EXHIBITS A Escrow Agreement B Non-Compete Agreements C Consulting Agreement AGREEMENT AND PLAN OF MERGER Agreement and Plan of Merger, dated as of July 9, 2007 (including the Schedules and Exhibits hereto, this “Agreement”), is by and among Noven Pharmaceuticals, Inc., a Delaware corporation (“Buyer”), Noven Acquisition, LLC, a Delaware limited liability company and a wholly-owned subsidiary of Buyer (“Merger Sub”), JDS Pharmaceuticals, LLC, a Delaware limited liability company (the “Company”), and Xxxxx Associates, LLC, solely in its capacity as Member Representative. Buyer, Merger Sub, the Company, and solely in its capacity as such and to the extent applicable, the Member Representative, are referred to collectively herein as the “Parties” and each individually as a “Party.”ARTICLE III

REPRESENTATIONS AND WARRANTIES REGARDING THE COMPANY GROUP. 17 Section 4.1.Organization 3.1 Organization; Authority; Enforceability 46 Section 3.2 Capitalization and Related Matters 46 Section 3.3 No Breach 47 Section 3.4 Financial Statements and Related Matters 48 Section 3.5 Absence of Undisclosed Liabilities 49 Section 3.6 No Company Material Adverse Effect 49 Section 3.7 Absence of Certain Developments 49 Section 3.8 Company Assets 50 Section 3.9 Tax Matters 50 Section 3.10 Company Material Contracts 52 Section 3.11 Intellectual Property Rights 55 Section 3.12 Data Security; Data Privacy 56 Section 3.13 Litigation 57 Section 3.14 Brokerage 57 Section 3.15 Labor Matters 57 Section 3.16 Employee Benefits 59 Section 3.17 Compliance with Laws; Permits 61 Section 3.18 Anti-Bribery; Anti-Corruption 64 Section 3.19 Anti-Money Laundering; Sanctions; Customs & Trade Laws 64 Section 3.20 Real Property 65 Section 3.21 Environmental 65 Section 3.22 Affiliate Transactions 66 Section 3.23 Investment Advisory Services 66 Section 3.24 Insurance 66 Section 3.25 Regulatory Compliance 66 Section 3.26 Company Funds 68 Section 3.27 Sufficiency of Assets 70 REPRESENTATIONS AND WARRANTIES OF PARENT, BLUE OWL GP, BLUE OWL HOLDINGS, BLUE OWL CARRY AND THE MERGER SUBS Section 4.1 Organization; Authorization; Enforceability 70 Section 4.2 Capitalization 71 Section 4.3 No Breach 72 Section 4.4 Absence of Undisclosed Liabilities 73 Section 4.5 No Parent Material Adverse Effect 73 Section 4.6 Absence of Certain Developments 73 Section 4.7 Brokerage 74 Section 4.8 Parent SEC Documents; Controls 74 Section 4.9 Information Supplied 75 Section 4.10 Tax Matters 75 Section 4.11 Litigation 76 Section 4.12 Compliance with Laws 76 Section 4.13 Regulatory Compliance 76 Section 4.14 Listing 77 Section 4.15 Merger Sub Business Activities 77 Section 4.16 Inspections; Company Representations 77 Section 4.17 Sufficient Funds 77 Section 4.18 Affiliate Transactions 78 Article V INTERIM OPERATING COVENANTS Section 5.1 Interim Operating Covenants of the Company and the Group 78 Section 5.2 Interim Operating Covenants of Parent 82 Article VI PRE-CLOSING AND OTHER COVENANTS Section 6.1 Company Group 17 Fund Consents 83 Section 4.2.Authorization 18 6.2 Commercially Reasonable Efforts; Further Assurances 85 Section 4.3.Noncontravention 18 6.3 Confidential Information 85 Section 4.4.Capitalization 18 6.4 Access to Information 86 Section 4.5.Subsidiaries of the Company 20 Section 4.6.Consents, Government Authorizations 20 Section 0.0.Xxxxxxxxx Statements 20 Section 4.8.Absence of Certain Changes 20 Section 0.0.Xxx Matters 21 Section 4.10.Real Property 22 Section 4.11.Intellectual Property 22 Section 4.12.Environmental Matters 23 Section 4.13.Contracts 23 Section 0.00.Xxxxxxxxx 25 Section 4.15.Litigation 26 Section 4.16.Employee Matters 26 Section 0.00.Xxxxx Compliance 28 Section 4.18.Brokers’ Fees 28 Section 4.19.Permits 28 Section 4.20.Transaction with Affiliates; Ownership of Assets 28 Section 0.00.Xx Additional Representations and Warranties 29 ARTICLE V. REPRESENTATIONS AND WARRANTIES REGARDING BUYER AND MERGER SUB 29 Section 5.1.Organization 29 Section 5.2.Authorization 29 Section 5.3.Noncontravention 29 Section 5.4.Consents, Government Authorizations 30 Section 0.0.Xxxxxxxxx Capacity 30 Section 5.6.Litigation 30 Section 5.7.Brokers’ Fees 30 Section 5.8.Information 30 ARTICLE VI. COVENANTS 31 Section 6.1.Conduct of the Company 31 Section 6.2.Access to Information; Confidentiality 33 Section 6.3.Efforts 34 Section 6.4.Approvals 34 Section 6.5.Public Announcements 35 Section 6.6.Notification 6.5 Notification of Certain Matters 35 87 Section 6.7.Director 6.6 Regulatory Approvals; Efforts 87 Section 6.7 Communications; Press Release; SEC Filings 89 Section 6.8 Expenses 90 Section 6.9 D&O Indemnification and Officer Indemnification 35 Insurance 90 Section 6.8.Employee Benefit Arrangements 36 6.10 Employee Matters 91 Section 6.9.Post6.11 Section 280G Matters 93 Section 6.12 Stock Transactions 94 Section 6.13 Merger Subs 94 Section 6.14 Exclusivity-Closing Access; Preservation of Records 37 Related Matters 94 Section 6.10.Further Assurances 37 6.15 Sellers’ Representative 95 Section 0.00.Xx Solicitation 37 Section 6.12.Supplemental Disclosure 38 Section 0.00.Xxx Treatment of Transactions. 38 Section 6.14.Purchase Price Allocation. 38 ARTICLE VII. CONDITIONS TO CLOSING 39 Section 7.1. Condition Precedent to Obligations of Buyer, Merger Sub and the Company 39 Section 7.2.Conditions Precedent to Obligation of the Company 40 Section 7.3.Conditions Precedent to Obligations of Buyer and Merger Sub 40 ARTICLE VIII. INDEMNIFICATION 41 Section 8.1.Survival 41 Section 8.2.Indemnification 42 Section 8.3.Indemnification Procedures 43 Section 8.4.Limitation on Liability 45 Section 8.5.Calculation of Damages 45 Section 8.6.Exclusive Remedy 46 Section 8.7.Access 46 Section 8.8.Mitigation of Damages 46 Section 8.9.Certain Damages 46 Section 8.10.Release of Escrow Amount 46 ARTICLE IX. MEMBER REPRESENTATIVE 47 Section 9.1.Member Representative 47 Section 9.2.Authority and Rights 47 Section 9.3.Limitations on Liability 48 ARTICLE X. TERMINATION 49 Section 10.1.Termination Events 49 Section 10.2.Effect of Termination 49 ARTICLE XI. MISCELLANEOUS 49 Section 11.1.Parties in Interest 49 Section 11.2.Assignment 49 Section 11.3.Notices 50 Section 11.4.Amendments and Waivers 51 Section 11.5.Exhibits and Disclosure Schedule 51 Section 11.6.Headings 52 Section 00.0.Xxxxxxxxxxxx 52 Section 00.0.Xx Other Representations or Warranties 52 Section 11.9.Entire Agreement 52 Section 11.10.Severability 52 Section 11.11.Expenses 53 Section 11.12.Governing Law 53 Section 11.13.Consent to Jurisdiction; Waiver of Jury Trial 53 Section 11.14.Equitable Remedies 53 Section 11.15.Counterparts 54 SCHEDULES Disclosure Schedule EXHIBITS A Escrow Agreement B Non6.16 Post-Compete Agreements C Consulting Agreement AGREEMENT AND PLAN OF MERGER Agreement and Plan of Merger, dated as of July 9, 2007 (including the Schedules and Exhibits hereto, this “Agreement”), is by and among Noven Pharmaceuticals, Inc., a Delaware corporation (“Buyer”), Noven Acquisition, LLC, a Delaware limited liability company and a wholly-owned subsidiary of Buyer (“Merger Sub”), JDS Pharmaceuticals, LLC, a Delaware limited liability company (the “Company”), and Xxxxx Associates, LLC, solely in its capacity as Member Representative. Buyer, Merger Sub, the Company, and solely in its capacity as such and to the extent applicable, the Member Representative, are referred to collectively herein as the “Parties” and each individually as a “Party.”Signing Actions 97 Article VII TAX MATTERS